Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal

We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April–June 2022, we implemented a case–case and cohort study and classified lineages using whole-genome sequencing or spike gene targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kislaya, Irina, Casaca, Pedro, Borges, Vítor, Sousa, Carlos, Ferreira, Bibiana I., Fonte, Ana, Fernandes, Eugénia, Dias, Carlos Matias, Duarte, Sílvia, Almeida, José Pedro, Grenho, Inês, Coelho, Luís, Ferreira, Rita, Ferreira, Patrícia Pita, Borges, Cláudia Medeiros, Isidro, Joana, Pinto, Miguel, Menezes, Luís, Sobral, Daniel, Nunes, Alexandra, Santos, Daniela, Gonçalves, António Maia, Vieira, Luís, Gomes, João Paulo, Leite, Pedro Pinto, Nunes, Baltazar, Machado, Ausenda, Peralta-Santos, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973705/
https://www.ncbi.nlm.nih.gov/pubmed/36737101
http://dx.doi.org/10.3201/eid2903.221367
Descripción
Sumario:We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April–June 2022, we implemented a case–case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case–case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93–1.23]) or booster (aOR 0.96 [95% CI 0.84–1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%–90%] vs. VE 93% [95% CI 86%–97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.

Ejemplares similares